Correlation-Aware Spatial-Temporal Graph Learning for Multivariate Time-Series Anomaly Detection.

Multivariate time-series anomaly detection is critically important in many applications, including retail, transportation, power grid, and water treatment plants. Existing approaches for this problem mostly employ either statistical models which cannot capture the nonlinear relations well or conventional deep learning (DL) models e.g., convolutional neural network (CNN) and long short-term memory (LSTM) that do not explicitly learn the pairwise correlations among variables. To overcome these limitations, we propose a novel method, correlation-aware spatial-temporal graph learning (termed ), for time-series anomaly detection. explicitly captures the pairwise correlations via a correlation learning (MTCL) module based on which a spatial-temporal graph neural network (STGNN) can be developed. Then, by employing a graph convolution network (GCN) that exploits one-and multihop neighbor information, our STGNN component can encode rich spatial information from complex pairwise dependencies between variables. With a temporal module that consists of dilated convolutional functions, the STGNN can further capture long-range dependence over time. A novel anomaly scoring component is further integrated into to estimate the degree of an anomaly in a purely unsupervised manner. Experimental results demonstrate that can detect and diagnose anomalies effectively in general settings as well as enable early detection across different time delays. Our code is available at https://github.com/huankoh/CST-GL.

The application of artificial intelligence to accelerate G protein-coupled receptor drug discovery.

The application of artificial intelligence (AI) approaches to drug discovery for G protein-coupled receptors (GPCRs) is a rapidly expanding area. Artificial intelligence can be used at multiple stages during the drug discovery process, from aiding our understanding of the fundamental actions of GPCRs to the discovery of new ligand-GPCR interactions or the prediction of clinical responses. Here, we provide an overview of the concepts behind artificial intelligence, including the subfields of machine learning and deep learning. We summarise the published applications of artificial intelligence to different stages of the GPCR drug discovery process. Finally, we reflect on the benefits and limitations of artificial intelligence and share our vision for the exciting potential for further development of applications to aid GPCR drug discovery. In addition to making the drug discovery process "faster, smarter and cheaper," we anticipate that the application of artificial intelligence will create exciting new opportunities for GPCR drug discovery.